Inhibrx announced that Chiesi Farmaceutici declined to exercise its option for the ex-North American rights to develop and commercialize INBRX-101 for the treatment of patients with emphysema due to Alpha-1 Antitrypsin Deficiency, or AATD. Inhibrx’s delivery of the European Medicines Agency, or EMA, scientific advice to Chiesi triggered a 60-day option period to obtain an exclusive license to develop and commercialize INBRX-101 for the treatment of patients with AATD outside of the United States and Canada. On September 18, 2023, Chiesi notified Inhibrx it was declining this option.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on INBX:
- Inhibrx sells 3.62M shares at $19.35 in private placement
- Inhibrx price target lowered to $27 from $35 at JMP Securities
- Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
- Inhibrx reports Q2 EPS ($1.08), consensus ($1.03)
- INBX Upcoming Earnings Report: What to Expect?
